Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma

Background. Renal cell carcinoma accounts for about 2-3% of all malignant tumors. The prevalence of brain metastases from RCC is less than 20% of cases. Traditionally, whole brain radiotherapy as well as the latest stereotactic radiosurgery improves both survival and local tumor control. These treat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Case Rep Oncol Med
Autors principals: Roberto, Michela, Bassanelli, Maria, Iannicelli, Elsa, Giacinti, Silvana, D'Antonio, Chiara, Aschelter, Anna Maria, Marchetti, Paolo
Format: Artigo
Idioma:Inglês
Publicat: Hindawi Publishing Corporation 2015
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4698998/
https://ncbi.nlm.nih.gov/pubmed/26798533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/629046
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars